The addition of the glucagon-like peptide-1 analogue semaglutide to standard of care resulted in sustained reduction in weight and waist circumference in individuals with type 2 diabetes (T2D) with high cardiovascular risk, according to the phase III SUSTAIN 6* trial presented at EASD 2017.
The addition of the sodium-glucose cotransporters 1 and 2 (SGLT1 and SGLT2) inhibitor sotagliflozin improved glycated haemoglobin levels, systolic blood pressure, and weight in patients with type 1 diabetes (T1D) on insulin therapy, according to findings of the InTandem3* trial presented at EASD 2017.
The risk of recurrence in patients with resected stage III BRAF-mutant melanoma can be reduced with adjuvant BRAF inhibitor and/or MEK inhibitor therapy, according to two phase III studies presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
Androgen deprivation therapy (ADT) carries an increased risk of certain cardiovascular disease (CVD) outcomes, namely heart failure, arrhythmia and conduction disorder, in men with localized prostate cancer, a recent study suggests.
The GLP-1* receptor agonist dulaglutide confers comparable glycaemic control with greater albuminuria reduction and less eGFR** decline compared with insulin glargine in patients with type 2 diabetes (T2D) and moderate-to-severe chronic kidney disease (CKD), when both were used in combination with the human insulin analogue lispro, according to the AWARD-7 study presented at the EASD Annual Meeting 2017 in Lisbon, Portugal.
Combination therapy with canagliflozin and insulin is effective in improving glycaemic control and reducing body weight and well tolerated by Japanese patients with type 2 diabetes mellitus (T2DM), according to a study presented at the 53rd European Association for the Study of Diseases (EASD 2017) held in Lisbon, Portugal.
Combination therapy with ramucirumab and docetaxeloffers a progression-free survival (PFS) advantage over docetaxel alone in patients with advanced or metastatic urothelial carcinoma (UC), according to results of the phase III RANGE trial presented at the European Society of Medical Oncology (ESMO) 2017 Congress held in Madrid, Spain.
New drug applications approved by US FDA as of 1 - 15 September 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
An 8-week regimen of sofosbuvir-velpatasvir-voxilaprevir combination is not noninferior to a 12-week regimen of sofosbuvir-velpatasvir for patients with chronic hepatitis C virus (HCV) infection, report two recent phase 3 open-label trials.
The interleukin-6 receptor-alpha inhibitor tocilizumab alone or in combination with methotrexate demonstrated clinical benefit after 2 years of treatment in methotrexate-naïve patients with early rheumatoid arthritis (RA), according to the FUNCTION* trial.
Addition of digoxin to an ACE inhibitor lessens heart failure (HF) hospitalisation in HF patients with reduced ejection fraction, regardless of diabetes status, as presented in an analysis of the Digitalis Investigation Group trial.